Esketamine Mechanism of Action: How Does Spravato Work in the Brain?
- Sophroneo Psychiatry
- Jul 4
- 12 min read
The simplest explanation of the esketamine mechanism of action is that esketamine blocks a type of glutamate receptor called the NMDA receptor. What happens after that blockade is still being studied.
That last sentence is important.
Esketamine is often described online as a drug that instantly “rewires the brain,” releases BDNF, and rebuilds synapses damaged by depression. Those ideas come from important neuroscience research, especially studies involving ketamine and laboratory models. However, the current FDA prescribing information for Spravato states that esketamine is a nonselective, noncompetitive NMDA receptor antagonist and that the exact mechanism by which it produces an antidepressant effect is unknown.
So, how does esketamine work?
The leading research model involves glutamate signaling, AMPA receptors, and neuroplasticity-related pathways. BDNF and mTOR may also be involved. But scientists are still working out which steps are necessary in humans and how directly findings from ketamine or animal studies apply to intranasal esketamine.
Here is the evidence-based version in plain language.
How does esketamine work?
Esketamine works at NMDA receptors, which are receptors involved in the brain's glutamate signaling system. Its antidepressant effects may involve a wider chain of changes in how neurons communicate and adapt.
Esketamine is the S-enantiomer of ketamine. An enantiomer is one of two molecular forms that are mirror images of each other. Spravato contains esketamine and is delivered as a nasal spray in a supervised healthcare setting.
The FDA label establishes one part of the mechanism clearly:
Esketamine is an NMDA receptor antagonist.
An antagonist reduces or blocks activity at a receptor.
The more complicated question is what NMDA receptor blockade does next.
A commonly studied model looks like this:
Possible step | Plain-language explanation | How certain is it? |
NMDA receptor antagonism | Esketamine blocks activity at NMDA glutamate receptors | Established pharmacology |
Altered glutamate signaling | NMDA blockade may change how glutamate is released and transmitted | Strong research support, mechanism still studied |
AMPA receptor activity | Glutamate signaling may shift toward AMPA receptor activation | Leading mechanistic model |
Plasticity-related signaling | AMPA activity may affect pathways associated with synaptic adaptation | Supported strongly by experimental research |
BDNF and mTOR pathways | These pathways may help support synaptic plasticity | Important research area, human findings remain incomplete |
Clinical symptom improvement | Some patients experience improvement in depressive symptoms | Supported by clinical trials, response varies |
The key is not to confuse a leading biological model with a fully proven sequence that occurs identically in every patient.
What are NMDA receptors and glutamate?
NMDA receptors are one type of receptor activated by glutamate, an important chemical messenger in the brain. Glutamate plays a major role in communication between neurons, learning, memory, and synaptic plasticity.
Synaptic plasticity means the ability of connections between brain cells to strengthen, weaken, or adapt.
The brain needs carefully regulated glutamate signaling. More glutamate is not automatically better, and less glutamate is not automatically healthier. What matters is how glutamate is released, where receptors are located, which brain circuits are involved, and how the overall network responds.
NMDA receptors are only one part of this system.
Another important glutamate receptor is the AMPA receptor. NMDA and AMPA receptors respond to glutamate but play different roles in neuronal signaling.
This is where the leading theory about rapid-acting antidepressant effects becomes more interesting.
What happens after esketamine blocks an NMDA receptor?
The leading theory is that NMDA receptor blockade changes glutamate signaling in ways that may increase AMPA-related activity and support neuroplasticity. The complete antidepressant pathway has not been conclusively established in humans.
The glutamate disinhibition theory
One widely studied explanation begins with inhibitory brain cells called GABAergic interneurons.
GABA is a major inhibitory neurotransmitter. In simple language, inhibitory neurons help regulate and restrain activity in other neurons.
Research involving ketamine suggests that NMDA receptor blockade on some inhibitory interneurons may reduce that restraint. This may temporarily allow certain glutamate-producing neurons to become more active.
This process is sometimes described as disinhibition.
Think of it less as pressing the gas pedal and more as briefly reducing pressure on a brake.
The result may be a short-lived change in glutamate signaling in brain regions involved in mood and cognitive function.
However, the phrase “glutamate surge” can make the process sound more settled or universal than the human evidence allows. It is more medically careful to say that NMDA receptor antagonism is thought to alter glutamatergic signaling.
Why AMPA receptors matter
AMPA receptors may be an important downstream part of the rapid antidepressant model.
When glutamate activates AMPA receptors, it can influence intracellular signaling involved in how synapses adapt and communicate. Experimental research on ketamine has linked AMPA receptor activity with several plasticity-related pathways.
This does not mean patients can feel AMPA receptors activating.
It also does not mean AMPA activation alone explains depression recovery.
Instead, researchers think the balance between NMDA and AMPA signaling may help explain why glutamate-targeting treatments behave differently from medications that primarily affect serotonin or norepinephrine.
What do BDNF and mTOR have to do with esketamine?
BDNF and mTOR are part of a leading neuroplasticity theory for ketamine-related antidepressant effects, but their exact role in intranasal esketamine treatment in humans is still being clarified.
BDNF, or brain-derived neurotrophic factor, is a protein involved in neuronal health and synaptic plasticity.
mTOR, or mechanistic target of rapamycin, is part of a cellular signaling pathway involved in protein production, cell growth, and other biological processes.
The proposed pathway is often simplified like this:
NMDA receptor blockade → altered glutamate signaling → AMPA receptor activity → plasticity-related signaling involving BDNF and mTOR
That model is useful, but it should come with an asterisk.
Human research involving ketamine has produced mixed BDNF findings. In one small randomized study of 22 people with treatment-resistant depression, plasma BDNF increased among ketamine responders compared with nonresponders. The study involved intravenous ketamine, not intranasal esketamine, so it should not be treated as direct proof of the Spravato mechanism.
This distinction is especially important for patient education.
Much of what scientists know about AMPA, BDNF, mTOR, and rapid synaptic changes comes from ketamine research and preclinical experiments. Esketamine is closely related to ketamine, but the two should not be treated as scientifically interchangeable in every claim.
Does esketamine actually rewire the depressed brain?
It is more accurate to say esketamine may influence neuroplasticity and brain-network function than to claim it has been proven to “rewire” or reverse damage in the depressed brain.
The word rewiring is attractive because it gives patients an easy mental picture. Unfortunately, it can also create a false impression that clinicians can watch damaged neural connections regrow in every person after a Spravato dose.
Human research is developing.
A 2025 proof-of-concept study followed seven patients with treatment-resistant depression receiving intranasal esketamine alongside oral antidepressants for six months. Researchers reported changes in the volume of several brain regions and fiber tracts associated with emotional regulation. The authors cautiously concluded that esketamine may promote structural changes related to mood regulation and neuroplasticity. The sample was extremely small, so the findings require larger studies before broad conclusions can be made.
What can patients reasonably take from that?
Neuroplasticity is a serious scientific area of esketamine research.
Human imaging research is beginning to examine possible structural and network changes.
It is too early to promise that Spravato repairs, rebuilds, or reverses brain damage in every patient.
Improvement in depression should be measured clinically, not assumed from a neuroscience theory.
A better phrase than “esketamine rewires your brain” is:
Esketamine may affect glutamate-related signaling and neuroplasticity in ways that contribute to antidepressant effects.
That is less dramatic, but medically more honest.
Why can esketamine act faster than traditional antidepressants?
Esketamine can produce measurable improvement in depressive symptom scores earlier than many traditional antidepressants in some patients. This may be related to its different effect on glutamate signaling, although the precise reason for the speed is not fully understood.
In a study summarized in the current FDA label, Spravato monotherapy showed statistically greater improvement than placebo at Day 2, approximately 24 hours after treatment, and the observed effect continued through Day 28 in that trial.
That does not mean every patient feels better within 24 hours.
Some patients may notice an early change. Others improve gradually. Some experience partial improvement, and some do not respond adequately.
Traditional antidepressants such as selective serotonin reuptake inhibitors, or SSRIs, primarily affect monoamine systems such as serotonin. Their clinical effects often develop over time through complex downstream adaptations.
Esketamine enters the depression treatment discussion through a different signaling system: glutamate.
That difference may help explain its faster clinical time course in some patients, but “fast acting” should never become “instant” or “guaranteed.”
Esketamine vs SSRIs: How are the mechanisms different?
Esketamine and SSRIs affect different neurotransmitter systems, although both may ultimately influence broader brain adaptation and plasticity.
Feature | Esketamine | SSRIs |
Primary receptor or signaling target | NMDA glutamate receptor antagonism | Serotonin transporter inhibition |
Major neurotransmitter system | Glutamate | Serotonin |
Common formulation | Supervised nasal spray for Spravato | Daily oral medication |
Treatment setting | Certified healthcare setting | Usually taken at home |
Early symptom changes | May occur relatively quickly in some patients | Benefits often develop over time |
Mechanism certainty | Antidepressant mechanism remains incompletely understood | Downstream antidepressant mechanism is also complex |
Neuroplasticity research | Strong focus on AMPA, BDNF, synaptic signaling, and network changes | Neuroplasticity also studied as a downstream effect |
Monitoring | At least two hours after Spravato administration | Depends on the medication and clinical plan |
This is not a contest between “old” and “new” antidepressants.
SSRIs continue to have an important role in depression care. Esketamine may be considered for specific adults with treatment-resistant depression. The treatment choice depends on diagnosis, previous treatment, safety factors, side effects, practical access, and patient preferences.
Patients considering advanced options may find it helpful to review broader depression treatment options with a licensed clinician.
What happens during a Spravato treatment session?
Spravato is administered as a nasal spray under direct healthcare supervision, followed by monitoring for at least two hours.
The official Spravato REMS program requires healthcare settings to be certified and requires supervised administration and post-dose monitoring.
Monitoring matters because possible risks include sedation, dissociation, respiratory depression, and increased blood pressure.
Dissociation may involve changes in how a person experiences their body, thoughts, surroundings, space, or time.
A treatment visit may include:
Pre-treatment safety review.
Blood pressure assessment.
Patient administration of the nasal spray under supervision.
Observation and symptom monitoring.
Additional blood pressure or respiratory monitoring as appropriate.
A clinical assessment before the patient leaves.
Patients should not drive or operate machinery until the next day after a restful sleep and need to arrange transportation home after treatment.
The FDA label's current treatment-resistant depression schedule begins with twice-weekly treatment during Weeks 1 through 4. It then moves to once weekly during Weeks 5 through 8, followed by once weekly or every two weeks from Week 9 onward, with frequency individualized to the least frequent dosing needed to maintain response or remission.
A licensed clinician can help determine what is appropriate.
Decision-support table: Is the esketamine mechanism relevant to your situation?
Use this table to prepare for a conversation with a clinician. It is not a diagnosis or treatment recommendation.
Your question or situation | Why the mechanism matters | What to ask |
Antidepressants have not helped enough | Esketamine works through a different primary receptor system | Does my history fit treatment-resistant depression? |
I want a faster-acting option | Clinical improvement may occur earlier in some patients | What is a realistic timeline for assessing my response? |
I have heard Spravato “regrows the brain” | Neuroplasticity is a research area, but strong claims can overstate human evidence | What is established versus theoretical? |
I am worried about dissociation | NMDA-related effects can alter perception during treatment | How will I be monitored if the experience is distressing? |
I am comparing Spravato and TMS | The treatments use different biological approaches | Which option fits my diagnosis and treatment history? |
I take several psychiatric medications | A full medication review is part of safe treatment planning | Are there interactions or monitoring concerns? |
I have major depression with acute suicidal ideation or behavior | Spravato has a specific FDA indication in conjunction with an oral antidepressant, but it has not been shown to prevent suicide or independently reduce suicidal ideation or behavior | What level of urgent care and safety support is needed? |
For mental health emergencies, please call 911.
Patients comparing advanced depression treatments may also want to understand how NeuroStar TMS for major depression differs from medication-based treatment.
Troubleshooting common questions about how esketamine works
Confusion often starts when a simplified neuroscience phrase is presented as established fact. Use these questions to clarify what a treatment provider means.
What you heard | Why it can be confusing | Better question to ask |
“Esketamine rewires the brain” | Rewiring is an imprecise metaphor | What human evidence supports neuroplasticity changes? |
“It creates new synapses within hours” | Much rapid synaptogenesis evidence comes from experimental models | Is this proven with intranasal esketamine in humans? |
“BDNF is why Spravato works” | BDNF is one proposed pathway, not the complete proven mechanism | How strong is the human BDNF evidence? |
“It works in 24 hours” | A study-level effect does not predict every patient's timeline | When and how will my symptoms be measured? |
“Glutamate is the depression chemical” | Depression cannot be reduced to one neurotransmitter | How does glutamate fit into the broader depression model? |
“Spravato is basically an SSRI, only faster” | The primary signaling targets are different | How does NMDA antagonism differ from serotonin reuptake inhibition? |
“Feeling dissociated means it is working” | A side effect is not proof of antidepressant response | How will you measure actual depression improvement? |
If you are taking psychiatric medication, medication management and treatment review can help put mechanism questions into the context of your actual treatment history. Do not change medication without guidance from your prescriber.
How Sophroneo fits
Sophroneo Behavioral Health & TMS can help patients understand whether Spravato fits into a broader depression care plan. Sophroneo's live service information confirms that it provides Spravato care and broader behavioral health services.
How Sophroneo may fit:
Spravato esketamine therapy is available for treatment-resistant depression and is administered in clinic with safety monitoring.
Psychiatric evaluations and medication management are available for children, adolescents, adults, and families.
Therapy, CBT, and other counseling approaches are available when clinically appropriate.
Telepsychiatry is available.
NeuroStar TMS is available as a non-drug therapy for major depressive disorder when antidepressants have not helped enough.
Sophroneo participates in most major insurance plans and accepts private pay. Coverage can vary. Confirm benefits with Sophroneo or your insurance provider.
Sophroneo serves patients at 4170 Old Austell Rd, Powder Springs, GA 30127, and 5300 Memorial Dr Suite 219B, Stone Mountain, GA 30083. The phone number is 770-999-9495.
Assumptions and limitations
This article assumes the reader is researching the esketamine mechanism of action in the context of depression and Spravato treatment. It does not diagnose depression or determine whether esketamine is appropriate for a specific person.
Important limitations include:
The FDA identifies esketamine as an NMDA receptor antagonist but states that its antidepressant mechanism is unknown.
The AMPA, BDNF, TrkB, mTOR, and synaptogenesis model is based on a combination of preclinical, ketamine, and developing human evidence.
Evidence about intravenous racemic ketamine should not automatically be treated as direct evidence about intranasal esketamine.
“Rewiring the brain” is a simplified metaphor, not a precise clinical description.
A 24-hour group-level effect in a clinical study does not mean every patient improves within one day.
Spravato does not work for everyone.
Side effects, benefits, and treatment fit can vary.
A licensed clinician should review diagnosis, treatment history, medications, medical conditions, and safety factors before recommending treatment.
Frequently Asked Questions
Is the esketamine mechanism of action fully understood?
No. Esketamine is known to be a nonselective, noncompetitive NMDA receptor antagonist. However, the FDA prescribing information states that the mechanism responsible for its antidepressant effect is unknown.
Researchers are studying altered glutamate signaling, AMPA receptor activity, BDNF, mTOR, synaptic plasticity, and brain-network changes as possible parts of the mechanism.
Does esketamine increase glutamate?
Esketamine is thought to alter glutamate signaling. Some leading models propose that NMDA receptor blockade on inhibitory interneurons can produce a temporary increase in glutamate transmission and greater AMPA receptor activity.
It is more cautious to describe this as a proposed mechanism than to say every Spravato dose produces a proven, identical “glutamate surge” in every patient's brain.
What is BDNF?
BDNF stands for brain-derived neurotrophic factor. It is a protein involved in neuronal health and synaptic plasticity.
BDNF is an important part of ketamine and esketamine research, but current human evidence does not establish a simple formula in which Spravato raises BDNF and therefore eliminates depression.
Does esketamine grow new brain cells?
It has not been proven that Spravato simply “grows new brain cells” in patients with depression.
Much of the research focuses on synaptic plasticity, meaning changes in how existing neurons connect and communicate. Synaptogenesis refers to the formation of new synaptic connections, which is different from producing entirely new neurons.
Does Spravato rewire your brain?
“Rewiring” is a simplified metaphor. Esketamine may influence glutamate-related signaling, neuroplasticity, and brain networks involved in depression.
Early human imaging studies are investigating structural and connectivity changes, but researchers cannot yet promise that Spravato predictably rebuilds specific brain regions in every patient.
Why can Spravato work faster than an SSRI?
Spravato acts primarily through NMDA glutamate receptor antagonism, while SSRIs primarily block serotonin reuptake.
The different signaling pathway may contribute to earlier symptom improvement in some patients. The exact biological reason for the faster clinical time course remains under investigation.
Is esketamine the same as ketamine?
No. Esketamine is the S-enantiomer of racemic ketamine.
Spravato is an FDA-approved intranasal esketamine product for specific adult depression indications. Racemic ketamine contains both S- and R-enantiomers and is commonly used off-label when given for depression.
Does a rapid response mean Spravato will work long term?
Not necessarily. Early improvement and long-term maintenance are different questions.
The treatment plan should include ongoing symptom measurement and periodic review of benefits, side effects, and treatment frequency. The FDA label recommends evaluating therapeutic benefit and individualizing maintenance frequency.
Can I stop my antidepressant if Spravato works?
Do not stop, reduce, or change antidepressant medication without guidance from your prescriber. The current FDA indication allows Spravato monotherapy for treatment-resistant depression in adults, but whether a person should use it alone or alongside another medication requires individualized clinical planning.
If depression has not improved enough with previous treatment and you want to understand whether the glutamate-based approach of esketamine is relevant to your history, consider scheduling an appointment for a careful evaluation and discussion of Spravato, TMS, therapy, medication management, or other appropriate care options.
Comments